Abstract
Skin photosensitivity remains the major side-effect of current clinical photodynamic therapy using porphyrin based drugs. We have studied the usefulness of oral activated charcoal in 12 patients undergoing photodynamic therapy and a control group of patients treated without charcoal. Detailed pharmacokinetic studies were carried out and measurements of skin erythema responses to known light doses were made using a reflectance spectrophotometer in these patients. There were no significant differences with respect to the area under the curve, clearance, mean residence time or half-life of the drug between the two groups and no significant differences in reflectance values. Prolonged skin photosensitivity as assessed by reflectance spectrophotometry was confirmed up to and beyond 2 months after treatment.
Similar content being viewed by others
References
Ho Y-K, Pandey RK, Missert JR et al. Carbon-14 labelling and biological activity of the tumour localising derivative of haematoporphyrin.Photochem Photobiol 1988,48:445–9
Tishler PV, Winston SH. Sorbent therapy of the porphyrias. IV. Absorption of porphyrins by sorbents in vivo.Meth and Find Exptl Clin Pharmacol 1985,7(9):485–91
Pimstone NR, Gandhi SN, Mukerji SK. Therapeutic efficacy of oral charcoal in congential erythropoietic porphyria.New England J Med 1987,316(7):390–3
Holroyd AJ, Vernon DI, Lowdell CP et al. A pharmacokinetic study of the drug polyhaematoporphyrin (Photofrin II) in patients undergoing photodynamic therapy (in press)
Gibaldi MBiopharmaceutics and Clinical Pharmacokinetics, 3rd ed. Philadelphia, USA: Lea and Febiger, 1984
Feather JW, Hajizadeh-Saffar, M, Leslie G, Dawson JB. A portable scanning reflectance spectrophotometer using visible wavelengths for the rapid measurement of skin pigments.Phys Med Biol 1989,34(7):807–20
Dawson B, Barker DJ, Ellis DJ et al. A theoretical and experimental study of light absorption and scattering by in vivo skin.Phys Med Biol 1980,25:695–709
Moan J, Christensen T, Sommer S. The main photosensitising components of haematoporphyrin derivative.Cancer Letters 1982,15:161–6
Bellnier DA, Dougherty TJ. The time course of cutaneous porphyrin photosensitisation in the murine ear.Photochem Photobiol 1989,49:369–73
Cowled PA, Forbes IJ. Photocytotoxicity in vivo of haematoporphyrin derivative components.Cancer Letters 1985,28:111–8
Moan J, Christensen T, Jacobsen PB. Porphyrin sensitised photoinactivation of cells in vitro. In: Doiron DR, Gomer CJ (eds)Porphyrin Localisation and Treatment of Tumours. New York: Alan R. Liss, 1984:91–114
Bellnier DA, Ho Y-K, Pandey RK et al. Distribution and elimination of Photofrin II in mice.Photochem Photobiol 1989,50(2):221–8
Gomer CJ, Dougherty TJ. Determination of [3H] and [14C] haematoporphyrin derivative distribution in malignant and normal tissues.Cancer 1979,38:146
Tralau CJ, Young AR, Walker NPJ et al. Mouse skin photosensitivity with Dihaematoporphyrin ether (DHE) and Aluminium sulphonated Phthalocyanine (AlSPc): A comparative study.Photochem Photobiol 1989,49(3):305–12
Amano T, Prout GR, Lin C-W. Intratumour injection as a more effective means of porphyrin administration for photodynamic therapy.J Urol 1988,139:392–5
Manyak M, Smith FS, Harrington FS et al. Protection against Dihaematoporphyrin ether photosensitivity.Photochem Photobiol 1988,47:823–30
Boyle DG, Potter WR. Photobleaching of Photofrin II as a means of eliminating skin photosensitivity.Photochem Photobiol 1987,46:997–1001
Roberts WG, Smith KM, McCullough JL, Berns MW. Skin photosensitivity and photodestruction of several potential photodynamic sensitizers.Photochem Photobiol 1989,49(4):431–8
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lowdell, C.P., Gilson, D., Ash, D.V. et al. An attempt to reduce skin photosensitivity in clinical photodynamic therapy using oral activated charcoal. Laser Med Sci 7, 351–356 (1992). https://doi.org/10.1007/BF02594072
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02594072